Table 4. Results of ASCT as first-line... | American Society of Hematology

Table 4.

Results of ASCT as first-line therapy for FL

Author	No. of patients	Source of stem cells	Conditioning regimen	Purging	Median follow-up, mo	DFS	OS
Voso et al⁴	70	PB	CY + TBI	CD34	44	78% at 44 mo	86% at 44 mo
Seyfarth et al¹⁶	33	PB	CY-TBI 78% BEAM 22%	0	48	76% at 4 y	92% at 4 y
Tarella et al³⁷	29	PB	MXT + L-PAM	10 of 29 Anti-B MoAbs	52	59% at 9 y	79% at 9 y
Morel et al³⁸	18	BM	BEAM	0	36	79% at 3 y	86% at 3 y
Horning et al³⁹	37	PB	CY + TBI	Anti-B MoAbs	78	60% at 10 y	86% at 10 y
Freedman et al⁴⁰	77	BM	CY + TBI	Anti-B MoAbs	45	66% at 3 y	89% at 3 y
Bociek et al⁴¹	43	PB	NP	0	36	36% at 5 y	63% at 5 y
Colombat et al⁴²	27	PB	CY + TBI	CD34⁺ or anti-B MoAbs	72	55% at 6 y	64% at 6 y
Gonzales-Barca et al⁴³	15	PB	CY + TBI	Anti-B MoAbs	56	83% at 4, 7 y	NP
Ladetto et al⁴⁴	98	PB	MXT-LPAM	0	30	58% at 30 mo	92% at 30 mo

Author	No. of patients	Source of stem cells	Conditioning regimen	Purging	Median follow-up, mo	DFS	OS
Voso et al⁴	70	PB	CY + TBI	CD34	44	78% at 44 mo	86% at 44 mo
Seyfarth et al¹⁶	33	PB	CY-TBI 78% BEAM 22%	0	48	76% at 4 y	92% at 4 y
Tarella et al³⁷	29	PB	MXT + L-PAM	10 of 29 Anti-B MoAbs	52	59% at 9 y	79% at 9 y
Morel et al³⁸	18	BM	BEAM	0	36	79% at 3 y	86% at 3 y
Horning et al³⁹	37	PB	CY + TBI	Anti-B MoAbs	78	60% at 10 y	86% at 10 y
Freedman et al⁴⁰	77	BM	CY + TBI	Anti-B MoAbs	45	66% at 3 y	89% at 3 y
Bociek et al⁴¹	43	PB	NP	0	36	36% at 5 y	63% at 5 y
Colombat et al⁴²	27	PB	CY + TBI	CD34⁺ or anti-B MoAbs	72	55% at 6 y	64% at 6 y
Gonzales-Barca et al⁴³	15	PB	CY + TBI	Anti-B MoAbs	56	83% at 4, 7 y	NP
Ladetto et al⁴⁴	98	PB	MXT-LPAM	0	30	58% at 30 mo	92% at 30 mo

PB indicates peripheral blood; BM, bone marrow; TBI, total body irradiation; CY, cyclophosphamide; MTX, mitoxantrone; L-PAM, melphalan; MoAbs, monoclonal antibodies; and NP, not provided.